HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 07, July 2017 – Food Science & Technology       » Scientists Demonstrate RNAi as an Antiviral Immunity in Mammals       » Singaporeans' Pain Costs Economy USD 6.2 billion Each Year       » China Fights Academic Paper Fraud After Peer Review Scandal       » Human Heart Tissue Grown from Stem Cells Improves Drug Testing       » Bioengineered Human Livers Mimic Natural Development       » Does Consuming Low-Fat Dairy Increase the Risk of Parkinson's Disease?      
EYE ON CHINA
Biogen Idec and UCB enter agreements to develop and commercialize multiple sclerosis and hemophilia therapies in China and other parts of Asia
Biogen Idec and UCB have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

"Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible," said Carlos Dourado, Senior Vice President, Emerging Markets at Biogen Idec. "By leveraging UCB's extensive resources, expertise and infrastructure in Asia, we believe we can grow our footprint in critical Asian markets, get our therapies to patients more quickly and create a foundation for further commercial success in this region."

"As a patient centric biopharmaceutical company, UCB is delighted to work with Biogen Idec on delivering some of the most important breakthrough products in the treatment of multiple sclerosis and hemophilia to patients in Asia," said Mohamed Chaoui, Head of Asia Pacific at UCB. "This partnership is a strong complement in our goal to offer innovative specialty care therapeutic options to patients suffering from severe diseases. It further supports our strategic goal to strengthen our leadership and expertise in biologics in both neurology and immunology in China and the Asian region."

Mr. Chaoui added, "We are committed to strengthening our presence in Asia and offering patients and healthcare providers in the Asian region access to new and innovative treatment options. This agreement is also an important step for our specialty focused expansion in China. It will help drive our business growth in key emerging markets, which is one of UCB's top strategic priorities."

Click here for the complete issue.

NEWS CRUNCH  
news Nestlé Introduces their Singapore R&D Centre
news Vitafoods Asia Elevates 2017 Learning Programme
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy